Skip to main content

Biogen Interferon revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Interferon revenue at Biogen came to $208.2M for the quarter to 30 Sep 2026, down 15.7% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$280.0MDec 2023$243.6MMar 2024$250.9MJun 2024$237.5MSep 2024$236.0MDec 2024$226.3MMar 2025$246.7MJun 2025$246.9MSep 2025$225.7MDec 2025$227.5MMar 2026$225.1MJun 2026$208.2MSep 2026
Biogen Interferon revenue, every reported period
Period endingInterferon revenueChange on a yearFiled
30 Sep 2026$208.2Mdown 15.7%28 Oct 2026
30 Jun 2026$225.1Mdown 8.8%29 Jul 2026
31 Mar 2026$227.5Mup 0.5%29 Apr 2026
31 Dec 2025$225.7Mdown 4.4%6 Feb 2026
30 Sep 2025$246.9Mup 4.0%30 Oct 2025
30 Jun 2025$246.7Mdown 1.7%31 Jul 2025
31 Mar 2025$226.3Mdown 7.1%1 May 2025
31 Dec 2024$236.0Mdown 15.7%12 Feb 2025
30 Sep 2024$237.5Mdown 14.5%30 Oct 2024
30 Jun 2024$250.9Mdown 17.0%1 Aug 2024
31 Mar 2024$243.6Mdown 0.8%24 Apr 2024
31 Dec 2023$280.0Mdown 9.6%14 Feb 2024
30 Sep 2023$277.7Mdown 17.4%8 Nov 2023
30 Jun 2023$302.4Mdown 13.6%25 Jul 2023
31 Mar 2023$245.6Mdown 20.7%25 Apr 2023
31 Dec 2022$309.6Mdown 18.0%15 Feb 2023
30 Sep 2022$336.0Mdown 13.3%25 Oct 2022
30 Jun 2022$350.2Mdown 12.5%20 Jul 2022
31 Mar 2022$309.6Mdown 22.7%3 May 2022
31 Dec 2021$377.7Mdown 17.2%3 Feb 2022
30 Sep 2021$387.5Mdown 18.3%20 Oct 2021
30 Jun 2021$400.4Mdown 16.8%22 Jul 2021
31 Mar 2021$400.5Mdown 14.1%22 Apr 2021
31 Dec 2020$456.0Mdown 11.7%3 Feb 2021
30 Sep 2020$474.1Mdown 10.5%21 Oct 2020
30 Jun 2020$481.4Mdown 13.2%22 Jul 2020
31 Mar 2020$466.0Mdown 7.0%23 Apr 2020
31 Dec 2019$516.5Mdown 13.5%6 Feb 2020
30 Sep 2019$530.0Mdown 10.2%22 Oct 2019
30 Jun 2019$554.4Mdown 11.4%24 Jul 2019
31 Mar 2019$500.9Mdown 9.0%24 Apr 2019
31 Dec 2018$597.1M—6 Feb 2019
30 Sep 2018$590.1Mdown 10.9%23 Oct 2018
30 Jun 2018$625.5Mdown 9.4%24 Jul 2018
31 Mar 2018$550.3M—24 Apr 2018
30 Sep 2017$662.0M—24 Oct 2017
30 Jun 2017$690.6M—25 Jul 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.